Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-label, Multi-center, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT07544056 is registered in ClinicalTrials.gov with BeBetter Med Inc as lead sponsor.

NCT NCT07544056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07544056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-label, Multi-center, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Lead sponsor
BeBetter Med Inc
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 4, 2026
Completion date
December 31, 2030
Enrollment
446 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced triple-negative breast cancer, metastatic triple-negative breast cancer